ceritinib soft gel capsules

Product Details:

Ph level none
Dosage As Per Direction By Physician
Physical Form capsules
Fermentation Smell Normal Smell
Ingredients other
Enzymatic Activity none

                                                                                                          SEND INQUIRY

Product Description

Ceritinib is a targeted therapy medication used in the treatment of certain types of cancer, specifically non-small cell lung cancer (NSCLC). Let’s explore a comprehensive description:

Indications: Ceritinib is primarily prescribed for the treatment of patients with metastatic NSCLC that is anaplastic lymphoma kinase (ALK)-positive. It is typically used in cases where other treatments have not been effective.

Mechanism of Action: Ceritinib is a tyrosine kinase inhibitor that specifically targets ALK, which is a gene that can undergo mutations leading to uncontrolled cell growth and cancer. By inhibiting ALK, ceritinib helps to block the signaling pathways that promote the growth of cancer cells.

Formulation: Ceritinib is available in the form of soft gel capsules for oral administration. The capsules are designed to enhance the absorption of the medication in the body.

Administration: Ceritinib is taken orally, usually once a day, with or without food. The specific dosage and treatment plan are determined by the healthcare provider based on the patient’s condition and individual factors.

Side Effects: Common side effects of ceritinib may include nausea, diarrhea, vomiting, fatigue, and increased liver enzyme levels. It’s important for patients to promptly report any unusual symptoms or side effects to their healthcare provider.

Precautions: Patients receiving ceritinib may undergo regular liver function tests due to the potential impact on the liver. It is not recommended during pregnancy, and effective contraception should be used during and for some time after treatment. Patients should inform their healthcare provider about any existing medical conditions or medications they are taking.

Conclusion: Ceritinib represents an important therapeutic option for individuals with ALK-positive metastatic NSCLC. Its targeted approach offers a more tailored and effective treatment option, and patients are encouraged to maintain open communication with their healthcare provider to address any concerns and ensure the most effective and well-tolerated treatment plan.

Main Heading Goes Here
Sub Heading Goes Here

No, thank you. I do not want.
100% secure your website.
Powered by
Scroll to Top